ALAMEDA, Calif., Jan. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that the Biotechnology Innovation Organization (BIO) has recognized OncoCyte Corporation as the Buzz of BIO winner in the “diagnostics and beyond category” for the 2017 BIO CEO & Investor Conference taking place February 13–14 at the Waldorf Astoria in New York. Nominated and selected by an online vote, contest winners are recognized as innovative and “buzzworthy” at the conference.
OncoCyte was selected because of its groundbreaking work in cancer confirmatory diagnostics that can help physicians better manage lung nodules to prevent avoidable procedures and reduce the overall cost of lung cancer screening. “We believe that our lung confirmatory test, which is currently in the development stage, has the potential to reduce a significant number of risky and avoidable biopsies,” commented William Annett, President & Chief Executive Officer.
In addition to being honored with the award, OncoCyte will make a company presentation as well as participate in partnering sessions during the Conference.
“We are honored by our peers and colleagues choosing us for the innovation award in our category and believe that this is a reflection of the unmet need for tools to help clinicians better manage patients with lung nodules,” said Dr. Kristine C. Mechem, Vice President of Marketing. “If we are successful with the final studies of our test, OncoCyte believes that we can significantly improve the standard of care for lung nodule management.”
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients.
While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. For more information visit www.oncocyte.com.
ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 19th Annual BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO CEO & Investor Conference draws business development executives from leading global pharmaceutical and established biotechnology companies.
Investor Contact: EVC Group, Inc. Michael Polyviou/Doug Sherk 646-445-4800 firstname.lastname@example.org / email@example.com